Silymarin slows Parkinson disease progression
- Trial ID
- NCT07001150
- Official Title
- Clinical Study Evaluating the Possible Role of Silymarin in Neuroprotection and Symptom Management in Parkinson's Disease
- Goal
- Silymarin slows Parkinson disease progression
- Phase
- PHASE2
- Status
- RECRUITING
- Sponsor
- Tanta University
- Study Type
- INTERVENTIONAL
- Enrollment
- 50 participants
- Conditions
- Parkinson Disease
- Interventions
- levodopa-carbidopa, Silymarin
Plain-Language Summary
The goal is to see whether silymarin, the active extract from milk thistle, can offer neuroprotection and help manage Parkinson's symptoms by reducing oxidative stress and inflammation that contribute to dopaminergic neuron damage. The approach adds oral silymarin to usual levodopa-carbidopa therapy; silymarin is not a dopamine replacement, it works as an antioxidant and anti-inflammatory agent, and the trial will monitor safety and any interactions with levodopa. This Phase 2 trial plans to enroll about 50 people, ages 45 to 65, who have Parkinson's and are already on dopamine replacement with Hoehn and Yahr stage 1 to 4. People who are pregnant or breastfeeding, have advanced liver disease, morbid obesity, poorly controlled diabetes, recent silymarin use, or other serious illnesses are excluded.
Locations
- Tanta Hospital for Mental Health, Tanta, Tanta, Qism 2, Egypt
Frequently Asked Questions
- What is this trial testing?
- This trial is studying levodopa-carbidopa. The goal is to see whether silymarin, the active extract from milk thistle, can offer neuroprotection and help manage Parkinson's symptoms by reducing oxidative stress and inflammation that contribute to dopaminergic neuron damage. The approach adds oral silymarin to usual levodopa-carbidopa therapy; silymarin is not a dopamine replacement, it works as an antioxidant and anti-inflammatory agent, and the trial will monitor safety and any interactions with levodopa. This Phase 2 trial plans to enroll about 50 people, ages 45 to 65, who have Parkinson's and are already on dopamine replacement with Hoehn and Yahr stage 1 to 4. People who are pregnant or breastfeeding, have advanced liver disease, morbid obesity, poorly controlled diabetes, recent silymarin use, or other serious illnesses are excluded.
- Who can participate?
- Participants must be between 45 Years and 65 Years.
- Where is this trial located?
- This trial is recruiting at 1 location.
- Does it cost anything to join?
- No. There is no cost to participate. Study-related care and treatment are provided at no charge.
- How long does the trial last?
- This Phase 2 trial is estimated to last approximately 1 year and 1 month.